63
Participants
Start Date
January 21, 2009
Primary Completion Date
September 30, 2017
Study Completion Date
March 8, 2018
Lenalidomide
Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
Dexamethasone
40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
Anticoagulants
Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
Reading Hospital and Medical Center, West Reading
WVU Mary Babb Randolph Cancer Center, Morgantown
Kinston Medical Specialists, Kinston
Emory University Winship Cancer, Atlanta
McFarland Clinic, Ames
Siouxland Hematology Oncology Associates, Sioux City
Waukesha Memorial Hospital (ProHealth Care), Waukesha
Aurora Cancer Center, Wauwatosa
Gundersen Lutheran, La Crosse
Metro MN CCOP, Saint Louis Park
Mayo Clinic, Rochester
University of IL at Chicago, Chicago
Missouri Valley Cancer Consortium, Omaha
Mayo Clinic in Arizona, Scottsdale
Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor, Ann Arbor
University of Pennsylvania, Philadelphia
Collaborators (1)
Celgene
INDUSTRY
PrECOG, LLC.
OTHER